Recombinant human erythropoietin - Max Planck Institute

Drug Profile

Recombinant human erythropoietin - Max Planck Institute

Latest Information Update: 26 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Max Planck Institute of Experimental Medicine
  • Class Antianaemics; Recombinant erythropoietins; Recombinant fusion proteins
  • Mechanism of Action Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Multiple sclerosis; Schizophrenia

Most Recent Events

  • 21 Sep 2006 Stem Cell Therapeutics has entered into an Option to Acquire agreement for the erythropoietin based therapies for the treatment of multiple sclerosis and schizophrenia
  • 21 Sep 2006 Phase-II clinical trials in Multiple sclerosis in Germany (unspecified route)
  • 21 Sep 2006 Phase-II clinical trials in Schizophrenia in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top